How Are Acromegaly Medications Administered?
At a Glance
Acromegaly medications are administered through long-acting monthly injections at a clinic, daily self-injections at home, or oral pills. The method depends on your specific prescription, such as octreotide, pegvisomant, or cabergoline, and whether your hormone levels are well-controlled.
The administration route of acromegaly medications is a major factor in daily life, and the options range from monthly clinic visits to daily self-injections or pills. The delivery method depends on the specific medication your endocrinologist prescribes, such as a somatostatin receptor ligand (SRL), a growth hormone receptor antagonist, or a dopamine agonist.
Quick Reference: Medication Administration
| Medication | Type | Route | Frequency | Given By | Storage |
|---|---|---|---|---|---|
| Octreotide LAR / Pasireotide LAR | Injectable SRL | Deep intramuscular (IM) | Usually every 4 weeks | Healthcare Professional | Refrigerated |
| Lanreotide | Injectable SRL | Deep subcutaneous | Usually every 4 weeks | HCP or Trained Patient/Partner | Refrigerated |
| Pegvisomant | GH Receptor Antagonist | Subcutaneous | Daily | Patient or Caregiver | Refrigerated |
| Oral Octreotide | Oral SRL | Pill (Capsule) | Twice daily | Patient | Refrigerated (until open) |
| Cabergoline | Dopamine Agonist | Pill (Tablet) | 1–2 times weekly | Patient | Room Temp |
Long-Acting Injections (Every 3 to 8 Weeks)
First-line medical therapies for acromegaly often involve first-generation Somatostatin Receptor Ligands (SRLs) like octreotide and lanreotide. These medications, along with second-generation options like pasireotide, are formulated to be long-acting and are typically given once every 4 weeks [1][2]. For patients whose hormone levels stabilize exceptionally well, doctors can sometimes extend the injection interval to every 6 to 8 weeks.
- Octreotide LAR and Pasireotide LAR: These medications require a deep intramuscular (IM) injection, usually into the gluteal muscle (the buttocks) [3][2]. Because the medication requires specific mixing and the needle is thick enough to reach deep into the muscle, these must be administered by a healthcare professional in a clinical setting [3]. The muscle will likely be sore for a few days, so avoiding sitting heavily on that side immediately after can help minimize discomfort.
- Lanreotide (Somatuline Depot): Unlike the intramuscular medications, lanreotide is administered as a deep subcutaneous (under the skin) injection [1][2]. While it is often given by a nurse or doctor, some patients or their trained partners can safely self-administer it at home [2]. Research shows patients generally report fewer injection-site problems and less anxiety with subcutaneous lanreotide compared to intramuscular octreotide [2][4]. Storage note: This medication must be kept in the refrigerator.
Daily Injections
For patients whose condition is not fully controlled by SRLs, or who experience side effects, doctors may prescribe a growth hormone receptor antagonist called Pegvisomant [5].
- How it is given: Pegvisomant requires a daily subcutaneous injection [5].
- Who administers it: Because it must be taken daily, patients or their caregivers self-administer the medication at home [6]. Comprehensive training from your healthcare team is critical; studies show that administration mistakes are common and can make the treatment less effective at controlling insulin-like growth factor 1 (IGF-1) levels [6]. Examples of these mistakes include improperly mixing the powder with the liquid (shaking it instead of gently rolling it) or failing to rotate injection sites. Storage note: The unmixed vials must be stored in the refrigerator.
Oral Medications (Pills)
For patients looking to avoid injections entirely, there are oral alternatives available.
- Cabergoline: This dopamine agonist is an oral pill usually taken just once or twice a week [7][8]. It is often prescribed for milder cases of acromegaly or as an “add-on” therapy alongside injections to help normalize IGF-1 levels [7][9]. It is safely stored at room temperature.
- Oral Octreotide (Mycapssa): This is an FDA-approved pill form of octreotide taken twice daily [10][11]. Currently, it is available for patients who have already achieved biochemical control—meaning their hormone levels (like IGF-1) are already stabilized on injectable SRLs and they tolerate the medications well [10][12]. Because food significantly reduces the absorption of the medication in the gut, these capsules must be taken on a strictly empty stomach—at least one hour before a meal or two hours after [13][14]. Switching to oral capsules has been shown to eliminate injection-site pain or nodules and improve overall treatment satisfaction [15][16]. Storage note: Unopened bottles must be refrigerated, though opened bottles can be kept at room temperature for up to a month.
Common questions in this guide
Can I take acromegaly medication as a pill instead of an injection?
Do I need to go to a clinic for my acromegaly injections?
How often do I need to take acromegaly injections?
Can I store my acromegaly medications at room temperature?
Why do I have to take oral octreotide on an empty stomach?
Related questions
Show more
Get notified when new evidence is published on Acromegaly.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Neuroendocrine tumours - Medical therapy: Biological.
Rinke A, Krug S
Best practice & research. Clinical endocrinology & metabolism 2016; (30(1)):79-91.
PMID: 26971845 - 2
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
Ström T, Kozlovacki G, Myrenfors P, Almquist M
Patient preference and adherence 2019; (13()):1799-1807 doi:10.2147/PPA.S213472.
PMID: 31695341 - 3
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD, Fleseriu M, Neggers S, et al.
BMC endocrine disorders 2016; (16()):16 doi:10.1186/s12902-016-0096-8.
PMID: 27039081 - 4
Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.
Gurel MH, Han Y, Stevens AL, et al.
BMC pharmacology & toxicology 2017; (18(1)):22 doi:10.1186/s40360-017-0124-y.
PMID: 28372573 - 5
Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Peral C, Cordido F, Gimeno-Ballester V, et al.
Expert review of pharmacoeconomics & outcomes research 2020; (20(1)):105-114 doi:10.1080/14737167.2019.1610396.
PMID: 31055976 - 6
Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study.
Cámara R, Venegas E, García-Arnés JA, et al.
Pituitary 2019; (22(2)):137-145 doi:10.1007/s11102-019-00943-1.
PMID: 30756345 - 7
Real-world value of cabergoline in the treatment of acromegaly.
Shimon I
Best practice & research. Clinical endocrinology & metabolism 2024; (38(4)):101887 doi:10.1016/j.beem.2024.101887.
PMID: 38443225 - 8
Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center.
Sahin S, Fidan MC, Korkmaz OP, et al.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2021; (129(9)):644-650 doi:10.1055/a-1274-1276.
PMID: 33096579 - 9
Cabergoline in acromegaly.
Kuhn E, Chanson P
Pituitary 2017; (20(1)):121-128 doi:10.1007/s11102-016-0782-6.
PMID: 28025719 - 10
Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly.
Uygur MM, Villanova M, Frara S, Giustina A
TouchREVIEWS in endocrinology 2024; (20(1)):37-42 doi:10.17925/EE.2024.20.1.9.
PMID: 38812667 - 11
Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly.
Yuen KCJ, Samson SL
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(6)):637-645 doi:10.1016/j.eprac.2022.04.009.
PMID: 35452815 - 12
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M, Dreval A, Bondar I, et al.
The lancet. Diabetes & endocrinology 2022; (10(2)):102-111 doi:10.1016/S2213-8587(21)00296-5.
PMID: 34953531 - 13
Update on the use of oral octreotide therapy for acromegaly.
Schilbach K, Schopohl J
Expert review of endocrinology & metabolism 2016; (11(4)):349-355 doi:10.1080/17446651.2016.1199954.
PMID: 30058923 - 14
A QbD-informed study of permeation enhancer-octreotide nanoscale interactions influencing performance in pullulan buccal films.
Malhotra S, Karki S, Linford H, et al.
International journal of pharmaceutics 2026; (694()):126730 doi:10.1016/j.ijpharm.2026.126730.
PMID: 41771310 - 15
MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly.
Fleseriu M, Molitch M, Dreval A, et al.
The Journal of clinical endocrinology and metabolism 2023; (108(12)):3214-3222 doi:10.1210/clinem/dgad365.
PMID: 37319438 - 16
Oral Octreotide Capsules and Paltusotine in Management of Acromegaly.
McLaren DS, Seejore K, Lynch J, Murray RD
TouchREVIEWS in endocrinology 2024; (20(1)):32-36 doi:10.17925/EE.2023.20.1.3.
PMID: 38812672
This page provides educational information about acromegaly medication administration and storage. Always consult your endocrinologist regarding your specific treatment plan, medication choices, and proper injection techniques.